Sign up
MGNX

MacroGenics Inc (NASDAQ: MGNX)

Healthcare · Biotechnology

$1.97−0.08 (−3.90%)

Last close · Nov 18, 2026 · NASDAQ USD

Set alert

The Quantellect read. MGNX fell 3.90% in the Nov 18 session to $1.97, which is 59.5% below its 52-week high of $4.86. Short interest is 8.75% of float with a 1.70% borrow fee. Two active firms cover the stock as of Nov 19, 2026; two active firms with targets average $8.50 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuationLower multiples than peers

P/S 0.9× vs peer median 13.9×

MomentumNeutral

RSI (14) 34.5 (overbought above 70, oversold below 30)

Trend—

—

Short interest8.8% of float

FINRA settlement Oct 30, 2026

MGNX price chart

Price $1.97 · As of Nov 18, 2026, 3:59 PM ET

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open
$2.02Nov 18, 2026 session
Previous close
$2.05Nov 17, 2026 close
Day range
$1.94 – $2.06Nov 18, 2026 session
52-week range
$1.33 – $4.86Through Nov 18, 2026
Volume
720.20KNov 18, 2026 session
Average volume (30 calendar days, 0 sessions)
—Through Nov 18, 2026
Market cap$152.88M
P/E (TTM)25.3
Forward P/E—
EPS (TTM)stale vendor snapshot —
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)1.34

Price history

MGNX · nasdaq · USD

Last completed session: Nov 18, 2026

Split-adjusted · volume in shares

November 2026 · 13 completed sessions
DateOpenHighLowCloseChangeVolume
2.022.0551.9351.97−0.08−3.902439%704,173
Open 2.02High 2.055Low 1.935
2.132.17992.022.05−0.12−5.529954%572,902
Open 2.13High 2.1799Low 2.02
2.222.251.93022.17−0.03−1.363636%886,958
Open 2.22High 2.25Low 1.9302
2.262.272.052.20−0.09−3.930131%997,842
Open 2.26High 2.27Low 2.05
2.312.432.242.29−0.03−1.293103%894,630
Open 2.31High 2.43Low 2.24
2.422.422.322.32−0.10−4.132231%451,230
Open 2.42High 2.42Low 2.32
2.312.432.312.42+0.08+3.418803%468,035
Open 2.31High 2.43Low 2.31
2.362.492.332.34+0.01+0.429185%953,368
Open 2.36High 2.49Low 2.33
2.262.4452.252.33+0.11+4.954955%695,812
Open 2.26High 2.445Low 2.25
2.302.33362.2052.22−0.09−3.896104%1,299,085
Open 2.30High 2.3336Low 2.205
2.392.462.232.31−0.02−0.858369%919,162
Open 2.39High 2.46Low 2.23
2.362.492.26012.330.000.00%409,139
Open 2.36High 2.49Low 2.2601
2.412.5352.322.33−0.07−2.916667%766,121
Open 2.41High 2.535Low 2.32

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 18

Insufficient data · Tide session Nov 18, 2026

Tide37Calm Tide—
Squeeze25Idle—
How the scores work →

How MGNX compares with its industry

Against 592 other US-listed Biotechnology stocks

Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%

Strongest points

  1. Latest-quarter year-over-year sales growth was 378%, higher than 93% of 592 peers.Peer median 0.0% · As of Nov 17, 2026
  2. One-year return was 30.5%, higher than 80% of 522 peers.Peer median −28.4% · As of Nov 17, 2026

Points of caution

  1. One-month return was -43.6%, with only 11% of 567 peers reporting a lower value.Peer median −13.8% · As of Nov 17, 2026
  2. Trailing-year net margin was -8.3%, with only 17% of 583 peers reporting a lower value.Peer median 0.0% · As of Nov 17, 2026
  3. Trailing-year return on equity was -225.8%, with only 18% of 554 peers reporting a lower value.Peer median −67.8% · As of Nov 17, 2026

Valuation

Lower multiples than peers

  • Price/sales0.87×13.90×
    Lowest 10%

    Higher than 7% of 407 peers

  • Forward P/E60.98×14.84×

    Not ranked: only 193 of 592 peers report it

  • Price/book3.57×2.57×

    Higher than 62% of 551 peers

Profitability

Profitability metrics are lower than most peers.

  • Gross margin−0.7%78.6%

    Not ranked: only 246 of 592 peers report it

  • Operating margin−42.2%0.0%

    Higher than 19% of 442 peers

  • Net margin−8.3%0.0%

    Higher than 17% of 583 peers

  • Return on equity−225.9%−67.8%

    Higher than 18% of 554 peers

Growth

Growth metrics are higher than most peers.

  • Quarterly sales growth, year over year378.0%0.0%
    Top 10% of peers

    Higher than 93% of 592 peers

  • 5-year sales growth rate7.3%11.6%

    Not ranked: only 139 of 592 peers report it

Balance sheet

Balance sheet metrics are lower than most peers.

  • Current ratio2.755.03

    Higher than 29% of 498 peers

  • Debt/equity (total borrowings)—0.23

    Not ranked: only 117 of 592 peers report it

Momentum

Returns are mixed versus peers.

  • 1-year return+30.5%−28.4%

    Higher than 80% of 522 peers

  • 6-month return−55.8%−26.6%

    Higher than 22% of 545 peers

  • 3-month return−51.6%−29.4%

    Higher than 22% of 558 peers

Compared with 592 other US-listed Biotechnology stocks · fundamentals as of Nov 1, 2026 · prices as of Nov 13, 2026

Upcoming events

— · Upcoming events not available

Analyst consensus

Insufficient coverage

0Strong Buy
2Buy
0Neutral
0Sell
0Strong Sell

Based on 2 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$6.00
Average$8.50
High$11.00

As of Nov 19, 2026 across 2 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q3 2026−$0.13−$0.32—
Q2 2026$0.26$0.31—
Q1 2026−$0.55−$0.58—
Annual 2025−$0.27−$1.18—
Q3 2025—$0.27—
Q2 2025—−$0.57—
Q1 2025—−$0.65—
Annual 2024−$0.59−$1.07—

Smart-money activity

In the last 60 days: 0 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
Insider sellPeters Jeffrey StuartSell$129.1KForm 4
13FPoint72 Asset Management, L.P.Reduced position$602.8K13F filing
13FCITADEL ADVISORS LLCReduced position$2.3M13F filing
13FMILLENNIUM MANAGEMENT LLCIncreased position$8.1M13F filing
13FTWO SIGMA INVESTMENTS, LPIncreased position$7.3M13F filing
13FD. E. Shaw & Co., Inc.Increased position$3.1M13F filing
13FRENAISSANCE TECHNOLOGIES LLCIncreased position$8.6M13F filing
13FPoint72 Asset Management, L.P.Opened position$401.1K13F filing
13FCITADEL ADVISORS LLCIncreased position$1.7M13F filing
13FMILLENNIUM MANAGEMENT LLCReduced position$3.2M13F filing
All smart-money activity →

News and press releases

All MGNX news →

Company profile

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic

CEO
Mr. Eric Blasius Risser
Headquarters
Rockville, MD, United States
Employees
293
IPO date
Oct 10, 2013
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.